Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (15666)	2/10/2005 11:45:16 AM
From: nigel bates	Read Replies (1) \| Respond to of 52153

CRXA / comments from GSK on potential Cervarix revenues... LONDON, Feb 10 (Reuters) - Financial analysts are underestimating the sales potential of Cervarix, GlaxoSmithKline Plc's (GSK.L) experimental vaccine for preventing cervical cnacer, the company's chief executive said on Thursday. "I think that the consensus of the financial analysts on Cervarix is too low," Jean-Pierre Garnier told a news conference. He later told Reuters that the current consensus for peak annual Cervarix sales was around $1 billion. GSK expects to file in 2006 for approval to market the product, which will compete with a rival treatment from Merck & Co Inc (MRK.N) . It is expected to take centre-stage at a research update on vaccines planned by GSK for June 30. "Our vaccine business is really going to expand dramatically because of Cervarix and rotavirus and other vaccines* which are in the works," Garnier said... ( several of which also use MPL)*